Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-27

Clinical Trial Update: FIRMAGON® Intensive Drug Monitoring

View source ↗

Summary

Results from an intensive drug monitoring study of FIRMAGON (degarelix) in prostate cancer have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Status: COMPLETED | Results posted: 2024-09-27